Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 9/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.47 |
| ▸ | MMEL1 | Q495T6 | 1/20 | 0.46 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.45 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.45 |
| ▸ | TACR1 | P25103 | 1/20 | 0.45 |
| ▸ | F2 | P00734 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6354184 | 0.90 | ACE (0.52) | ACELMNASMN1; SMN2ACE2CTRB1 | |
| SCHEMBL6352076 | 0.86 | ACE (0.54) | ACELMNASMN1; SMN2ACE2CTRB1 | |
| SCHEMBL6353403 | 0.84 | ACE (0.50) | ACELMNASMN1; SMN2CTRB1 | |
| SCHEMBL23659223 | 0.83 | CYP3A4 (0.52) | LMNASMN1; SMN2CYP3A4CYP2C9PKM | |
| SCHEMBL2180711 | 0.83 | CYP3A4 (0.52) | LMNASMN1; SMN2CYP3A4CYP2C9PKM | |
| SCHEMBL194807 | 0.83 | CYP3A4 (0.52) | LMNASMN1; SMN2CYP3A4CYP2C9PKM | |
| SCHEMBL28629505 | 0.79 | MEN1 (0.54) | CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL6354580 | 0.79 | F2 (0.48) | ACEF2 | |
| SCHEMBL9140655 | 0.79 | ACE (0.50) | ACEACE2CTRB1ITGB1ITGA4 | |
| SCHEMBL11332304 | 0.78 | ACE (0.52) | ACELMNAACE2CTRB1TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050222093-A1 | Methods for restoring cognitive function following systemic stress | PEARLMAN RODNEY | 2005-10-06 | — | — | US | claimed |
| EP-1372620-A2 | METHODS FOR RESTORING COGNITIVE FUNCTION FOLLOWING SYSTEMIC STRESS | Saegis Pharmaceuticals (US) | 2004-01-02 | — | — | EP | claimed |
| US-20020187977-A1 | Methods for restoring cognitive function following systemic stress | SAEGIS PHARMACEUTICALS, INC. | 2002-12-12 | — | — | US | claimed |
| WO-2002074293-A2 | METHODS FOR RESTORING COGNITIVE FUNCTION FOLLOWING SYSTEMIC STRESS | SAEGIS PHARMACEUTICALS INC (US) | 2002-09-26 | — | — | WO | claimed |
| US-20050222093-A1 | Methods for restoring cognitive function following systemic stress | PEARLMAN RODNEY | 2005-10-06 | — | — | US | disclosed |
| EP-1372620-A2 | METHODS FOR RESTORING COGNITIVE FUNCTION FOLLOWING SYSTEMIC STRESS | Saegis Pharmaceuticals (US) | 2004-01-02 | — | — | EP | disclosed |
| US-20020187977-A1 | Methods for restoring cognitive function following systemic stress | SAEGIS PHARMACEUTICALS, INC. | 2002-12-12 | — | — | US | disclosed |
| WO-2002074293-A2 | METHODS FOR RESTORING COGNITIVE FUNCTION FOLLOWING SYSTEMIC STRESS | SAEGIS PHARMACEUTICALS INC (US) | 2002-09-26 | — | — | WO | disclosed |
| US-5439930-A | Biologically active n-acylprolydipeptides having antiamnestic, antihypoxic and anorexigenic effects | RUSSIAN-AMERICAN INSTITUTE FOR NEW DRUG DEVELOPMENT (US) | 1995-08-08 | — | — | US | disclosed |
| WO-1993021216-A1 | BIOLOGICALLY ACTIVE N-ACYLPROLYLDIPEPTIDES HAVING ANTIAMNESTIC, ANTIHYPOXIC AND ANOREXIGENIC EFFECTS | RUSSIAN-AMERICAN INSTITUTE FOR NEW DRUG DEVELOPMENT (US) | 1993-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222093-A1 | Methods for restoring cognitive function following systemic stress | CRH, BDNF, CHAT | ACE 97/4885LMNA 4098/4885SMN1; SMN2 764/4885 |
| US-20020187977-A1 | Methods for restoring cognitive function following systemic stress | CRH, BDNF, CHAT | ACE 97/4885LMNA 4098/4885SMN1; SMN2 764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.